| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) |
| Creator | Vasseur et al. |
| Author | Antoine Vasseur |
| Author | Luc Cabel |
| Author | Olivier Tredan |
| Author | Marion Chevrier |
| Author | Coraline Dubot |
| Author | William Jacot |
| Author | Anthony Goncalves |
| Author | Marc Debled |
| Author | Christelle Levy |
| Author | Jean-Marc Ferrero |
| Author | Christelle Jouannaud |
| Author | Elisabeth Luporsi |
| Author | Marie-Ange Mouret-Reynier |
| Author | Florence Dalenc |
| Author | Alexia Savignoni |
| Author | Marie-Laure Tanguy |
| Author | Jean-Yves Pierga |
| Abstract | BACKGROUND: Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757). METHODS: The main baseline criteria were HER2-negative mBC, performance status 0-2 and no prior chemotherapy for metastatic disease. CECs were detected by CellSearch® from 4 ml of blood at baseline and after 4 weeks of weekly paclitaxel and bevacizumab therapy. CEC counts (considered both as a continuous variable and using the previously described 20 CEC/4 ml cutoff) were associated with clinical characteristics and progression-free survival (PFS). RESULTS: CEC count was obtained in 251 patients at baseline and in 207 patients at 4 weeks. Median baseline CEC count was 22 CEC/4 ml (range 0-2231). Baseline CEC counts were associated with performance status (p?=?0.02). No statistically significant change in CEC counts was observed between baseline and 4 weeks of therapy. High baseline CEC count was associated with shorter PFS in univariate and multivariate analyses (continuous: p? |
| Publication | Angiogenesis |
| Date | Nov 26, 2019 |
| Journal Abbr | Angiogenesis |
| Language | eng |
| DOI | 10.1007/s10456-019-09697-7 |
| ISSN | 1573-7209 |
| Short Title | Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 31773439 |
| Tags | Bevacizumab, Circulating endothelial cells, original |
| Date Added | 2020/01/21 - 10:47:17 |
| Date Modified | 2020/01/21 - 11:26:22 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
